AC Immune reports positive Parkinson's and NLRP3 data in Q3 2026 update

AC Immune SA reported on November 4, 2026 that its Parkinson's disease candidate ACI-7104 received FDA Fast Track designation and clearance of its Investigational New Drug application during the period.¹ The company also disclosed positive safety and immunogenicity results reported through week-100 in Part 1 of VacSYn, the ongoing Phase 2 trial evaluating ACI-7104 in patients with early-stage Parkinson's disease.¹

On the immune response, the company said there was a 100% response rate after three immunizations, clear antibody penetration into the cerebrospinal fluid (CSF) and preliminary signals for target engagement.¹ Separate analysis work turned up trends for a potential association between immunogenicity (antibody levels) and disease activity measures¹ in early exploratory work. Further characterization of the antibodies is expected before year-end, and the company plans discussions with FDA regarding future development path planned for early 2027.¹

In the NLRP3 inhibitor program, Phase 1 testing of ACI-19764 in healthy volunteers found the compound safe and well-tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration.¹ Based on pharmacokinetic results, the therapeutic dose is expected to be ≤10mg once daily.¹ A Phase 1b trial testing ACI-19764 in patients with elevated hsCRP is ongoing, with initial results expected early in 2027.¹

The company also said it selected a lead candidate Morphomer small-molecule drug targeting a-syn, with preclinical development now initiated to take the candidate forward.¹

On finances, AC Immune reported cash resources of CHF 73.9 million as of September 30, 2026, providing cash runway into Q1 2028.¹